Latest Factor VIII Stories
LAGUNA NIGUEL, Calif., Oct. 19 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the U.S.
HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA has received confirmation of orphan drug exclusivity from the U.S.
BUENOS AIRES, Argentina, July 12 /PRNewswire/ -- Bayer HealthCare announced today that it awarded more than $2.5 million in funding to 19 recipients from 10 countries through its Bayer Hemophilia Awards Program (BHAP).
WAYNE, N.J., June 28 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched FactorTrack(TM), the first customizable mobile application for people with hemophilia A.
Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.
RALEIGH, N.C., Feb. 23 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world.
LACHEN, Switzerland, Jan. 13 /PRNewswire/ -- Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilateÂ® from the U.S. Food and Drug Administration (FDA).
HOBOKEN, N.J., Dec. 7 /PRNewswire/ -- Octapharma USA today announced the U.S. Food and Drug Administration has approved wilateÂ® for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD).
SOUTH PLAINFIELD, N.J., Oct. 26 /PRNewswire/ -- PTC Therapeutics, Inc.
- A woman chauffeur.
- A woman who operates an automobile.